SNDX-5613 Chemical Properties

Boiling point:

739.1±70.0 °C(Predicted)

Density 

1.28±0.1 g/cm3(Predicted)

solubility 

DMSO:30.0(Max Conc. mg/mL);47.56(Max Conc. mM)

pka

11.10±0.40(Predicted)

form 

Solid

color 

White to off-white

InChIKey

FRVSRBKUQZKTOW-YOCNBXQISA-N

SMILES

C(N(CC)C(C)C)(=O)C1=CC(F)=CC=C1OC1=CN=CN=C1N1CC2(CCN(C[C@@H]3CC[C@@H](NS(CC)(=O)=O)CC3)CC2)C1

SNDX-5613 Usage And Synthesis

Uses

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].

in vivo

References

[1] A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).

SNDX-5613(2169919-21-3)Related Product Information

• SNS-062
• PF-04929113
• 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide
• N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride
• N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea